Kristine Peterson was appointed Director of Mineralys Therapeutics, Inc., effective October 19, 2026. As of November 6, 2026, Mineralys Therapeutics, Inc. has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from August 11, 2026 to November 4, 2026, naming 2 appointments (Form 8-K, October 19, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Mineralys Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-11-04
- · In / out: In · Person: Kristine Peterson · Role: Director · Effective: 2026-10-19 · 8-K, 2026-10-19
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-08-11
Mineralys Therapeutics, Inc. reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-08-11 to 2026-11-04. They name 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as Mineralys Therapeutics, Inc. files it.
Also on the record for Mineralys Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 5.1% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Catalys Pacific Fund, LP | 10.1% of the class | 5%+ stakes | Source |
| February 5, 2026 | Stake report, Schedule 13G, by FMR LLC | 6.3% of the class | 5%+ stakes | Source |
| January 21, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.2% of the class | 5%+ stakes | Source |
| September 8, 2025 | Stake report, Schedule 13D/A, by RA Capital Management, L.P. | 9.9% of the class | 5%+ stakes | Source |
| September 8, 2025 | Stake report, Schedule 13D/A, by Samsara BioCapital, L.P. | 8.2% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Andera Partners | 4.2% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Catalys Pacific Fund, LP | 13.5% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Mineralys Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Mineralys Therapeutics, Inc. and the records around it.
Mineralys Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- Andera Partners also filed stake reports on 2 other companies: Inventiva S.A. (Oct 2026), EVOMMUNE, INC. (Aug 2026)
- Samsara BioCapital, L.P. also filed stake reports on 14 other companies: PMV Pharmaceuticals, Inc. (Sep 2026), Eloxx Pharmaceuticals, Inc. (Aug 2026), RANI THERAPEUTICS HOLDINGS, INC. (May 2026)
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026), SOLID BIOSCIENCES INC. (Nov 2026)
Watch Mineralys Therapeutics, Inc.
Get an email when Mineralys Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Mineralys Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Mineralys Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Mineralys Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-11-04 | Reported | not named in the filing | 8-K, 2026-11-04 | ||
| 2026-10-19 | In | Director | 2026-10-19 | 8-K, 2026-10-19 | |
| 2026-10-19 | In | Director | 8-K, 2026-10-19 | ||
| 2026-08-11 | Reported | not named in the filing | 8-K, 2026-08-11 |
Who leads Mineralys Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Kristine Peterson, appointed, effective 2026-10-19 (filed 2026-10-19).
New leaders reset buying decisions — get the Full Report on Mineralys Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Mineralys Therapeutics, Inc., with the record behind each one.
Find candidates like Director at Mineralys Therapeutics, Inc.Every change, in the filing's words
Reported
On October 29, 2026, Derek DiRocco, Ph.D. informed the Board of Directors (the Board) of the Company of his decision to resign from the Board, effective as of December 31, 2026.
- Dr. DiRocco advised the Company that his decision was not the result of any disagreement with the Company or its management on any matter relating to the Company's operations, policies, or practices.
Appointed: Kristine Peterson, Director, effective 2026-10-19
On October 16, 2026, the Board of Directors (the Board) of Mineralys Therapeutics, Inc. (the Company) appointed Kristine Peterson and Lonnel Coats to the Board effective as of October 19, 2026, increasing the size of the Board from seven to nine directors.
Appointed: Lonnel Coats, Director
Mr. Coats was appointed as a Class II director, with a term expiring at the Company's 2028 annual meeting of stockholders, and was also appointed to serve as a member of the Compensation Committee.
- Ms. Peterson was appointed as a Class I director, with a term expiring at the Company's 2027 annual meeting of stockholders, and was also appointed to serve as a member of the Audit Committee.
- Pursuant to the Company's non-employee director compensation program, on October 19, 2026, Ms. Peterson and Mr. Coats were each granted an option to purchase 16,600 shares of the Company's common stock.
- The option awards vest in substantially equal monthly installments over a three-year period following October 19, 2026, subject to continued service on the Board.
- On October 19, 2026, Ms. Peterson and Mr. Coats were also each granted a restricted stock unit award covering 12,400 shares of the Company's common stock.
- The restricted stock unit awards vest in substantially equal annual installments over a three-year period following October 19, 2026, subject to continued service on the Board.
- Ms. Peterson and Mr. Coats will receive cash compensation for their service on the Board in accordance with the Company's non-employee director compensation program, as such program may be amended from time to time.
Reported
On August 5, 2026, the Company's Board of Directors (the Board) appointed James J. Ferguson III, M.D., as the Company's new Chief Medical Officer, effective August 10, 2026, replacing David Rodman, M.D., who remains with the Company on a full-time basis as a Strategic Advisor.
- In connection with this transition, the Board also completed a detailed review of Dr. Rodman's new functions and responsibilities and, based upon such review, determined that he no longer satisfies the definition of "officer" set forth in Rule 16a-1(f) promulgated under the Exchange Act or the definition of "executive officer" set forth in Rule 3b-7 under the Exchange Act.
- On August 5, 2026, Dr. Rodman entered into an amendment to his Amended and Restated Employment Letter Agreement (the Amendment) to reflect his transition into a Strategic Advisor role, effective August 10, 2026.
Tools for this story
Each opens in a new tab, filled in for Mineralys Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.